Clinical Trials
18 trialsNCT02645149 2026-02-27
Match Mel
Melanoma Institute Australia
Phase 2 Completed
NCT03671330 2025-10-31
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Novartis
Phase 2 Completed
NCT03822468 2025-10-16
AMALEE
Novartis
Phase 2 Completed
NCT02632045 2024-12-06
MAINTAIN
Columbia University
Phase 2 Completed
NCT03070301 2024-10-10
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03839823 2024-10-09
RIGHT Choice
Novartis
Phase 2 Completed
NCT05163106 2024-08-02
NEOLETRIB
University Hospital, Akershus
Phase 2 Completed
NCT03484923 2024-06-18
PLATforM
Novartis
Phase 2 Completed
NCT02035813 2024-06-04
DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
University of Ulm
Phase 2 Completed
NCT02159066 2024-03-05
LOGIC-2
Pfizer
Phase 2 Completed
NCT03477396 2024-02-20
Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Completed
NCT03555877 2023-07-07
AMICA
GBG Forschungs GmbH
Phase 2 Completed
NCT02657928 2021-10-26
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
Mayo Clinic
Phase 2 Completed
NCT03078751 2021-10-11
EarLEE-1
Novartis
Phase 2 Completed
NCT03248427 2021-03-17
CORALLEEN
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT02420691 2020-10-30
Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02300987 2020-10-26
A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression
Novartis
Phase 2 Completed
NCT02187783 2019-07-18
SIGNATURE
Novartis
Phase 2 Completed